Head-to-head · free
Neuronetics, Inc. vs TScan Therapeutics, Inc.
STIM vs TCRX — return on capital, cash generation, margins and balance sheet side by side.
STIM
5 / 6
measures where STIM leads
TCRX
1 / 6
measures where TCRX leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | STIM · FY2025 | TCRX · FY2025 |
|---|---|---|
| Revenue | $149.2M | $10.3M |
| Net income | (39.0M) | (129.8M) |
| Revenue growth (yearly, multi-year) | 28.1% | 0.5% |
| Free cash flow | — | (139.7M) |
| Free cash flow margin | — | -1353.3% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -155.7% | -71.3% |
| Gross margin | 48.5% | — |
| Operating margin | -21.1% | -1315.4% |
| Net debt / EBITDA | -1.35x | 0.90x |
Figures are as reported by each company; latest fiscal year shown.
Where Neuronetics, Inc.'s cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where TScan Therapeutics, Inc.'s cash went (FY2025)
- Capital spending
- $4.4M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free